Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme spinoffs?

This article was originally published in The Gray Sheet

Executive Summary

Firm announces plans to pursue "strategic alternatives" for its genetic testing, diagnostic products and pharmaceutical intermediates businesses. Management is exploring divestiture, spin-out or management buyout, Genzyme disclosed on May 6. Genzyme will also initiate a $2 billion stock buyback. The initiatives are designed to increase shareholder value, CEO Henri Termeer told analysts

You may also be interested in...

Genzyme's Genetic Testing Business Attracts $925 Million From LabCorp

Genzyme's marginally profitable genetic testing service business is being sold to Laboratory Corporation of America for $925 million, the firms announced Sept. 13

Sanofi-Aventis' Interest In Genzyme May Include Diagnostics Arm

Drug maker Sanofi-Aventis is signaling potential interest in Genzyme's molecular diagnostics business, suggesting that the unit could be retained if Sanofi succeeds in its quest to acquire Genzyme

FDA Clarifies Software Link In Abbott COVID-19 Lab Test Recall

The recall is related to the software’s mixing parameters, which may cause false positives if test samples contaminate each other.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts